UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION 

Washington,
D.C. 20549

 

FORM
6-K

 

REPORT
OF FOREIGN PRIVATE ISSUER

PURSUANT
TO RULE 13a-16 OR 15d-16

UNDER
THE SECURITIES EXCHANGE ACT OF 1934

 

For
the month of April 2026

 

Commission
File Number: 001-42915

 

Alps
Group Inc

(Registrant’s
Name)

 

Unit
E-18-01 & E-18-02, Level 18, Icon Tower (East)

No.
1, Jalan 1/68F, Jalan Tun Razak

50400
Kuala Lumpur

Wilayah
Persekutuan, Malaysia

(Address
of Principal Executive Offices)

 

Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form
20-F ☒ Form 40-F ☐

 

Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

Appointment of Board Member

 

The
board of directors (“Board”) of Alps Group Inc ( “Company”) announces that Mr. Hee H. Lee (“Mr.
Lee”) has been appointed as a director of the Company, effective April 17, 2026. In connection with the appointment,
the number of members of the Board will increase from five (5) to six (6). Mr. Lee is independent pursuant to applicable Nasdaq rules.

 

Mr.
Lee has over 30 years of experience in the financial services sector. He served as a Partner at Ernst & Young LLP from July 2013
to June 30, 2025, during which period he established and led the Americas Financial Accounting Advisory Services practice.
In addition, he served as an advisor to the International Swaps and Derivatives Association for more than 20 years.

 

Mr.
Lee holds a Master of Accountancy and Financial Information Systems from Cleveland State University and a Bachelor of Business Administration
from the University of Louisiana at Lafayette. He is a Certified Public Accountant licensed in the State of New York.

 

The
Board believes Mr. Lee will bring abroad extensive and relevant professional experience to the Company. Mr. Lee is expected to serve
as a member of both the Audit Committee and the Compensation Committee of the Board.

 

The
Company issued a press release on April 17, 2026 announcing the appointment of the director, and is furnished as Exhibit 99.1.

 

 

Exhibits

 

Exhibit
No.
 
Description

99.1*
 
Press Release dated April 17, 2026

 

 

SIGNATURES

 

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.

 

 
Alps Group Inc

 
 
 

Date:
April 17, 2026
By:
/s/
Dr. Tham Seng Kong

 
Name:
Dr.
Tham Seng Kong

 
Title:
Chief
Executive Officer and Director

 

 

 

Exhibit
99.1

 

 

Alps
Group Appoints Former Ernst & Young Partner to Board of Directors, Strengthening Governance and Capital Markets Oversight

 

KUALA
LUMPUR, Malaysia, April 17, 2026 – Alps Group Inc (the “Company” or “Alps Group”), the parent company
of Alps Life Sciences Inc. (“Alps Holdco”), a biotechnology research and healthcare platform focused on predictive,
preventive, and precision medicine, announced the appointment of Mr. Hee H. Lee (“Mr. Lee”) to its Board of Directors
(the “Board”), effective April 17, 2026. The Company’s Board will increase from five (5) to six (6) directors
in connection with this appointment. Mr. Lee is considered independent under applicable Nasdaq rules and is expected to serve as a member
of the Audit Committee and the Compensation Committee.

 

Mr.
Lee has over 35 years of experience in the public accounting and advisory services, including his tenure as a Partner at Ernst &
Young LLP (“EY”) within its Global Financial Services Organization. During his career, Mr. Lee advised boards of directors
and senior management of financial institutions on financial reporting, corporate governance, structured transactions, and capital markets
matters.

 

At
EY, Mr. Lee established and led the Americas Financial Accounting Advisory Services (“FAAS”) practice within the financial
services sector. His experience spans asset management, banking, insurance, private equity, and fintech/digital assets. He has advised
on derivatives, securitization, structured financing, initial public offerings, and mergers and acquisitions, and served for more than
20 years as an advisor to the International Swaps and Derivatives Association (“ISDA”), contributing to the development
and interpretation of industry standards affecting global capital markets.

 

Mr.
Lee is a Certified Public Accountant licensed in the State of New York and a member of the American Institute of Certified Public Accountants.
He holds a Master of Accountancy and Financial Information Systems from Cleveland State University and a Bachelor of Business Administration
from the University of Louisiana at Lafayette. He has also completed executive education programs in board and leadership development
at Harvard University and the Kellogg School of Management.

 

“Mr.
Lee’s experience in financial reporting, governance, and capital markets will strengthen the Board’s oversight and support
the Company’s ongoing development as a public company,” said Dr. Tham Seng Kong, Chief Executive Officer of Alps Group.

 

“I
am pleased to join the Board of Alps Group Inc and look forward to contributing to the Company’s strategic direction and governance
framework. The Company’s focus on healthcare innovation is aligned with my professional and personal interests, and I look forward
to working with the Board and management team.” said Mr. Lee.

 

 

 

About
Alps Group

 

Alps
Group Inc is the parent company of Alps Life Sciences Inc., an integrated biotechnology platform integrating research and development,
medical services, and wellness solutions of advanced therapies under one unified ecosystem aimed at improving healthcare outcomes globally.
Alps Group’s mission is to create a fair healthcare ecosystem, to make advance predictive, preventive, and precision medicine accessible
and affordable.

 

Forward-Looking
Statements

 

Certain
statements in this press release may be considered to contain certain “forward-looking statements” within the meaning of
“safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified
by words such as: “target,” “believe,” “expect,” “will,” “shall,” “may,”
“anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,”
“intend,” “plan,” “project” and other similar expressions that predict or indicate future events
or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of
future performance. Instead, they are based only on the Company management’s current beliefs, expectations, and assumptions. Because
forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that
are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated
in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

 

A
further list and description of risks and uncertainties can be found in documents filed with the Securities and Exchange Commission (“SEC”)
by the Company and other documents that we may file or furnish with the SEC, which you are encouraged to read. Any forward-looking statement
made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which
it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may
be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.

 

Investor
Relations Contact

 

Alps
Group Inc

Email:
investorrelations@alpsmedical.com